House Moves Closer To Senate On FDA Bill
This article was originally published in The Gray Sheet
Executive Summary
The chart compares provisions in the latest available versions of House and Senate FDA user fee reauthorization and reform bills.
You may also be interested in...
Fireworks Kept At Bay As Congress Pushes To Enact FDA Reforms By July 4
Bipartisan FDA user fee reauthorization and reform legislation sailed unanimously through the House Energy and Commerce Committee May 10, with many similarities to a Senate version that has also passed out of committee.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.